HER3
Assets acting on this target.
- Class
- HER3 (ERBB3)-directed
- Pathway
- HER3/ERBB3 signaling
- Notes
- original target text: HER3 (ERBB3)
HER3 (ERBB3) is a member of the epidermal growth factor receptor (EGFR/HER) family of cell-surface receptors that regulate cell growth and survival. Unlike its relatives EGFR and HER2, HER3 has a catalytically weak (pseudokinase) intracellular domain, so it functions mainly by pairing with other HER-family members, especially HER2, to transmit growth signals into the cell. This partnership strongly activates the PI3K/AKT pathway, a central driver of cell survival and proliferation, and HER3 upregulation is a common route by which tumors resist therapies aimed at EGFR or HER2. Because HER3 itself lacks strong enzymatic activity, it is difficult to block with conventional small-molecule inhibitors, which has favored antibody-based approaches, including antibody-drug conjugates (ADCs) that use a HER3-binding antibody to deliver a cytotoxic payload directly into HER3-expressing cells. This mechanism broadly matters in cancers such as non-small cell lung cancer and breast cancer, particularly in settings where HER3 expression contributes to disease progression or treatment resistance, offering a way to target tumor cells that other HER-directed therapies leave unaffected.
Related mechanisms
HER3 drugs compared
7 drugs, stage by indication
| Drug | Developer | Modality | Furthest stage | Stage by indication |
|---|---|---|---|---|
| Beruzatatug pelitecan | BioNTech, MediLink Therapeutics (Suzhou) Co., Ltd. | antibody-drug conjugate | Phase 3 | Phase 3 in HR+/HER2- Metastatic Breast Cancer; Phase 3 in Non-Small Cell Lung Cancer |
| Patritumab Deruxtecan | Daiichi Sankyo, Merck & Co. | antibody-drug conjugate | Phase 3 | Phase 3 in Breast Cancer; Phase 3 in HR+/HER2- Metastatic Breast Cancer; Phase 3 in Non-Small Cell Lung Cancer |
| Ruzaltatug rezetecan | Jiangsu Hengrui Pharmaceuticals | antibody-drug conjugate | Phase 3 | Phase 3 in Non-Small Cell Lung Cancer |
| AK138D1 | Akeso | antibody-drug conjugate | Phase 1/2 | Phase 1/2 in Non-Small Cell Lung Cancer |
| DB-1310 | DualityBio Inc. | antibody-drug conjugate | Phase 1/2 | Not recorded |
| ENV-501 | Hummingbird Bioscience | antibody-drug conjugate | Phase 1/2 | Phase 1/2 in Non-Small Cell Lung Cancer |
| Nezutatug | Hummingbird Bioscience | monoclonal antibody | Phase 1/2 | Phase 1/2 in Non-Small Cell Lung Cancer |